Dicembre 2013 - Volume XXXII - numero 10
Farmacoriflessioni
1Clinica Pediatrica, IRCCS Materno-Infantile “Burlo Garofolo”, Università di Trieste
2UOC di Pediatria e Neonatologia, Azienda Ospedaliera di Ravenna
Indirizzo per corrispondenza: irene.berti@burlo.trieste.it
Key words: Infantile haemangioma, Propranolol, Case report
Infantile Haemangiomas (IE) are common benign tumours, affecting around 10% of the new borns. Natural history goes towards a spontaneous regression in most cases, although in long times (years) and sometimes with some imperfect outcome. Propranolol has been recently proposed as a very effective treatment for IE, without relevant side effects. The number of children treated is increasing very quickly, but currently there are neither uniform guidelines nor shared protocols. Basing on available data it can be said that propranolol is very safe and the current recommendations for cardiovascular monitoring may probably be simplified. For very superficial lesions and at the very beginning, topical timolol can be used successfully.
Vuoi citare questo contributo?